TSLP Treatment Using Oligonucleotide siRNA and ASO Compositions

ChangeBridge: Patent Apps - Biotech (C12N)

Published May 19th, 2025

Detected April 2nd, 2026

Summary

The USPTO published patent application US20260091053A1 disclosing oligonucleotide compositions (siRNA and antisense oligonucleotides) targeting Thymic Stromal Lymphopoietin (TSLP) for treatment of TSLP-related diseases. The application covers methods of treating airway disorders by administering oligonucleotides specific to the long isoform of TSLP. Inventors include Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, and David Rozema. The application was filed on May 19, 2025.

View original document View source feed page

What changed

US20260091053A1 is a newly published USPTO patent application disclosing compositions and methods for treating TSLP-related diseases using small interfering RNA (siRNA) or antisense oligonucleotide (ASO) therapeutics that target long-form TSLP transcripts. The patent covers therapeutic applications for airway disorders and includes claims to oligonucleotide compositions targeting the long isoform of TSLP (lfTSLP). Application No. 19212537 was filed on May 19, 2025.

Pharmaceutical and biotech companies developing TSLP-targeting therapeutics should review this patent application to assess potential freedom-to-operate concerns. While patent applications do not yet grant enforceable rights, applicants may begin marketing discussions or seek licensing. If the patent grants, it would provide exclusive rights to the claimed compositions and treatment methods, potentially affecting competitive positioning in the TSLP therapeutics space.

What to do next

Review patent claims for potential infringement if developing TSLP-targeting therapeutics
Assess freedom-to-operate for siRNA/ASO compositions targeting TSLP
Monitor prosecution history for claim amendments during examination

Source document (simplified)

← USPTO Patent Applications

TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS

Application US20260091053A1 Kind: A1 Apr 02, 2026

Inventors

Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA

Abstract

Provided are compositions comprising an oligonucleotide that targets Thymic stromal lymphopoietin (TSLP). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating an airway disorder by providing an oligonucleotide that targets TSLP to a subject in need thereof. In some embodiments, the oligonucleotide targeting is specific for a long isoform of TSLP (lfTSLP).